Amarin Corp Plc (AMRN)

[ilovetech]

HDK, well-phrased always. Three seasoned Federal Judges will pick the DC ruling apart, irrespective of their individual political leanings. En banc review acts as a check to reign in any individual Judge from falling victim to their individual biases.

HDK, I was wondering if you read Bhatt's Epeleuton study? More specifically, the data points that are "relevant" to those studied in Reduce-it to see how they fared head to head? Let's assume Epeleuton showed improved biomarkers over Vascepa. We don't know if any marginal improvement would translate to better CVD RRR? I.E., are there thresholds beyond which cause a diminished benefit, or even further, that could result in harm? Obviously, we're not looking to eliminate biomarkers that our bodies can't do without.


ILT